Urologic Cancer

Genitourinary Oncology Program

 

The University of Chicago Urologic Cancer Program
The University of Chicago is a world leader in the treatment of prostate, kidney, bladder, testes, adrenal, and penile cancers. Urologists at the University of Chicago specialize in the latest and most effective open and laparoscopic operations, incorporating nerve-sparing techniques, laparoscopic and minimally-invasive technologies, and novel combinations of surgical and medical treatments.

 

Our objective is to effectively eradicate cancer while minimizing the effects on the patient’s general health and his ( and his family’s) lifestyle. In combination with colleagues in Medical Oncology, Radiation and Cellular Oncology, and the Cancer Research Center, we offer a comprehensive and diverse option of therapies for patients with urologic cancers.

 


New Cancer Therapies Program
The objective of the New Cancer Therapy Program is to apply the latest surgical techniques, medical technologies, and pharmaceutical agents to the treatment of urologic cancers. The program was created to develop, advance, and subsequently offer state-of-the-art treatments to patients with urologic cancers by incorporating these novel anti-cancer agents and technologies as a compliment to conventional surgical therapy.

 

Many clinical trials are offered in the Section of Urology designed to study how to best treat urologic cancers with the least deleterious effects on the patient.

 

  • Projects in the New Cancer Therapies Program currently include:
  • Anti-angiogenesis therapy for men with high risk and locally-advanced prostate cancer.
  • Complement-based immune therapy for men with kidney and prostate cancer.
  • Minimally-invasive and laparoscopic approaches to the treatment of prostate and kidney cancer.
  • Alternative energy source (i.e. HIFU and cryotherapy) treatment of prostate and kidney cancers.
  • Treatment of locally-recurrent prostate cancer after radiotherapy.


For more details on anti-cancer clinical trials, click here.
For more details on the New Cancer Therapies Program, click here.

 

Translational Research Program
The mission of the Translational Research Program is to integrate clinical and laboratory research efforts to improve the management of patients with urologic cancers.

 

The primary objective is to develop, advance, and subsequently offer state-of-the-art treatments to patients with urologic cancers by developing improved therapies and treatment paradigms that incorporate novel anti-cancer agents and technologies as a compliment to conventional surgical therapy. In translational research, discoveries from the laboratory are applied directly to patient care while observations from the clinic are explored at the laboratory bench.

 

The Translational Research Program is founded on the following philosophical triumvirate:

 

  • Combining conventional surgical therapies with both standard and experimental adjuvant treatments.
  • Embracing minimally-invasive technologies and expanding their role in patient care.
  • Advocating investigator-initiated clinical trials designed in the true spirit of translational research, in which laboratory discoveries are applied to patient management and observations from the clinic are explored at the bench. Correlative scientific investigation will aid in improved understanding of molecular, genetic, and biochemical pathophysiologic processes of these cancers and in the creation of better management strategies.
     

Urologists at the University of Chicago specialize in the latest and most effective approaches to the management of urologic cancers. This includes the incorporating nerve-sparing techniques, performing laparoscopic and minimally-invasive technologies, and combining surgical and medical anti-cancer treatments.

 

The Translational Research Program is involves participation from both clinical and research faculty from throughout the University of Chicago and the urologic cancer research community at large.

 

For more details on basic research opportunities in the Section of Urology, click here.
For more details on the New Cancer Therapy Program and Clinical Trials offered in the Section of Urology, click here.

 

Basic Urology Research Laboratory
Scientists from within the Section of Urology and throughout the University are committed to enhancing the management of patients with urologic cancers. To accomplish this goal, biochemical, genetic, and molecular biologic studies are performed to improve our fundamental understanding of cancer biology and how to better target cancer cells with surgical and medical approaches.

 

Research projects within the Section of Urology Basic Research Laboratory include the following:

 

  • Studying the role of metastasis suppressor genes in cancer development and progression.
  • Exploring how to effectively target metastatic and metastatic-prone cancer cells and incorporate this therapeutic approach into conventional anti-cancer treatments.
  • Investigating the use of anti-angiogenesis agents as an anti-cancer therapy and better understanding how stromal-epithelial interactions can be used as a therapeutic target.
  • Researching the use of immunologic agents as an anti-cancer therapeutic modality and better understanding how the immune system is involved in the development and progression of cancer.
  • Understanding the role of nutrition, especially fatty acids, on the development and progression of prostate cancer.